Contraception
Volume 67, Issue 1 , Pages 9-13 , January 2003

Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial

  • Marni Kwiecien

      Affiliations

    • Department of Obstetrics and Gynecology, Oregon Health and Science University, Mail Code L-466, Portland, OR 97201, USA
    • ,
  • Alison Edelman

      Affiliations

    • Department of Obstetrics and Gynecology, Oregon Health and Science University, Mail Code L-466, Portland, OR 97201, USA
    • ,
  • Mark D. Nichols

      Affiliations

    • Department of Obstetrics and Gynecology, Oregon Health and Science University, Mail Code L-466, Portland, OR 97201, USA
    • ,
  • Jeffrey T. Jensen

      Affiliations

    • Department of Obstetrics and Gynecology, Oregon Health and Science University, Mail Code L-466, Portland, OR 97201, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-503-494-5113; fax: +1-503-494-5083.

Received 3 July 2002 ,Revised 16 September 2002 ,Accepted 19 September 2002.

References 

  1. Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 mcg ethinylestradiol/100 mcg levonorgestrel and 20 mcg ethinylestradiol/500 mcg norethisterone. Contraception. 2001;64:3–10
  2. Reisman H, Martin D, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 mcg levonorgestrel with 20 mcg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. Am J Obstet Gynecol. 1999;181:45–52
  3. Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms (a multicenter, randomized, open-label study). Eur J Contracept Reprod Health Care. 1999;4:75–83
  4. Abraham S, Fraser I, Gebski V, et al.  Menstruation, menstrual protection and menstrual cycle problems. The knowledge, attitudes and practices of young Australian women. Med J Aust. 1985;142:247–251
  5. Burkman RT, Bell WR, Zacur HA, Kimball W. Oral contraceptives and antithrombin III (variations by dosage and ABO blood group). Am J Obstet Gynecol. 1991;164:1453–1460
  6. Heinemann LA. Emerging evidence on oral contraceptives and arterial disease. Contraception. 2000;62(Suppl 2):S29–S38
  7. Bousser MGS, Kittner J. Oral contraceptives and stroke. Cephalalgia. 2000;20:183–189
  8. Coney P, Washenik K, Langley RG, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with a low-dose oral contraceptive (two randomized, placebo-controlled trials). Contraception. 2001;63:297–302
  9. Kirkman RJ, Pedersen JH, Fioretti P, Roberts HE. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception. 1994;49:33–46
  10. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives (a randomized trial of 20 micrograms and 35 micrograms estrogen preparations). Contraception. 1999;60:321–329
  11. MacGregor A. Migraine associated with menstruation. Funct Neurol. 2000;15:143–153
  12. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini G, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77:52–61
  13. Loudon NB, Foxwell M, Potts DM, Guild AL, Short RV. Acceptability of an oral contraceptive that reduces the frequency of menstruation (the tri-cycle pill regimen). Br Med J. 1977;2:487–490
  14. Miller L. Continuous administration of 100 mcg levonorgestrel and 20 mcg ethinyl estradiol for elimination of menses (a randomized trial). Obstet Gynecol. 2001;97:S16
  15. Archer DF, Maheux R, DelConte A, O’Brien FB. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 mcg levonorgestrel and 20 mcg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol. 1999;181:39–44
  16. Hulley S, Cummings BSR. Designing clinical research. Baltimore: Williams & Wilkins; 1988;
  17. Miller LK, Notter M. Menstrual reduction with extended use of combination oral contraceptive pills (randomized controlled trial). Obstet Gynecol. 2001;98:771–778
  18. Boerrigter PJ, Ellman H, Dolker M. International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 mcg and ethinyl estradiol 20 mcg. Clin Ther. 1999;21:118–127
  19. Fraser I S, Hickey M, Song J Y. A comparison of mechanisms underlying disturbances of bleeding caused by spontaneous dysfunctional uterine bleeding or hormonal contraception. Hum Reprod 1996;11 Suppl2: S165–S78
  20. Egarter C, Putz M, Strohmer H, Speiser P, Wenzl R, Huber J. Ovarian function during low-dose oral contraceptive use. Contraception. 1995;51:329–333
  21. Spona J, Elstein M, Feichtinger W, et al.  Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–77
  22. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181:1263–1269
  23. Davis A, Wysocki S. Clinician/patient interaction (communicating the benefits and risks of oral contraceptives). Contraception. 1999;59(Suppl 1):S39; S–S42

PII: S0010-7824(02)00445-6

Contraception
Volume 67, Issue 1 , Pages 9-13 , January 2003

Article Tools

* Image Usage & Resolution